1. Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinson’s Dis [Internet]. 2018 [cited 2021 Jul 3];4:21. Available from: https://www.nature.com/articles/s41531-018-0058-0 DOI: 10.1038/s41531-018-0058-0
2. Wissler Gerdes EO, Zhu Y, Weigand BM, Tripathi U, Burns TC, Tchkonia T, et al. Cellular senescence in aging and age-related diseases: implications for neurodegenerative diseases. Int Rev Neurobiol [Internet]. 2020 [cited 2021 Jul 3];155:203–34. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656525/ DOI: 10.1016/bs.irn.2020.03.019
3. Young CB, Reddy V, Sonne J. Neuroanatomy, basal ganglia [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2021 Jul 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537141/
4. Gandhi KR, Saadabadi A. Levodopa (L-Dopa) [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Jul 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482140/
5. Metman LV. Recognition and treatment of response fluctuations in Parkinson's disease: review article. Amino Acids [Internet]. 2002 [cited 2021 Jul 3];23(1–3):141–5. Available from: https://pubmed.ncbi.nlm.nih.gov/12373528/DOI: 10.1007/s00726-001-0119-1
6. Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm [Internet]. 2018 [cited 2021 Jul 3];125:1237–1250. Available from: https://link.springer.com/article/10.1007/s00702-018-1869-1 DOI: 10.1007/s00702-018-1869-1
7. BlueRock Therapeutics. BlueRock Therapeutics receives FDA fast track designation for DA01 in the treatment of advanced Parkinson’s disease. 2021 Jul 19. BlueRock Therapeutics [Internet]. Available from: https://bluerocktx.com/news/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease/
8. Chaudhari R, Tan Z, Huang B, Zhang S. Computational polypharmacology: a new paradigm for drug discovery. Expert Opin Drug Discov [Internet]. 2017 [cited 2021 Jul 3];12(3):279–91. Available from: https://www.tandfonline.com/doi/full/10.1080/17460441.2017.1280024 DOI: 10.1080/17460441.2017.1280024
9. Walton CC, Andersen JK. Unknown fates of (brain) oxidation or UFO: close encounters with neuronal senescence. Free Radic Biol Med [Internet]. 2019 [cited 2021 Jul 3];134:695–701. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0891584918326182 DOI: 10.1016/j.freeradbiomed.2019.01.012
10. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol [Internet]. 2014 [cited 2021 Jul 3];5:99–118. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166495/ DOI: 10.1146/annurev-pathol-121808-102144
11. Van Deursen JM. The role of senescent cells in ageing. Nature [Internet]. 2014 [cited 2021 Jul 3];509(7501):439–446. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214092/ DOI: 10.1038/nature13193
12. Chinta SJ, Woods G, Demaria M, Rane A, Zou Y, McQuade A, et al. Cellular senescence is induced by the environmental neurotoxin Paraquat and contributes to neuropathology linked to Parkinson’s disease. Cell Rep [Internet]. 2018 [cited 2021 Jul 3];22(4):930–40. Available from: https://www.cell.com/action/showPdf?pii=S2211-1247(17)31929-0 DOI: 10.1016/j.celrep.2017.12.092
13. Riessland M, Kolisnyk B, Kim TW, Cheng J, Ni J, Pearson JA, et al. Loss of SATB1 induces p21-dependent cellular senescence in post-mitotic dopaminergic neurons. Cell Stem Cell [Internet]. 2019 [cited 2021 Jul 3];25(4):514–30. Available from: https://www.sciencedirect.com/science/article/pii/S1934590919303480 DOI: 10.1016/j.stem.2019.08.013
14. Riessland M. Is cellular senescence of dopaminergic neurons the cause of local inflammation in the midbrain observed in Parkinson’s disease? J Cell Immunol [Internet]. 2020 [cited 2021 Jul 3];2(5):201–4. Available from: https://www.scientificarchives.com/admin/assets/articles/pdf/is-cellular-senescence-of-dopaminergic-neurons-the-cause-of-local-inflammation-in-the-midbrain-observed-in-parkinsons-disease-20200804110848.pdf
15. Piao J, Zabierowski S, Dubose BN, Hill EJ, Navare M, Claros N, et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell [Internet]. 2021 [cited 2021 Jul 3];28(2):217–29. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1934590921000047 DOI: 10.1016/j.stem.2021.01.004
16. ClearPoint Neuro, Inc. First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform. 2021 Jun 8. ClearPoint Neuro, Inc [Internet]. Available from: https://ir.clearpointneuro.com/company-information/press-releases/detail/1040/clearpoint-neuro-inc-congratulates-bluerock-therapeutics
17. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron [Internet]. 2003 [cited 2021 Jul 3];39(6):889–909. Available from: https://www.sciencedirect.com/science/article/pii/S0896627303005683 DOI: 10.1016/S0896-6273(03)00568-3
18. Jasiak NM, Park JM. Immunosuppression in solid-organ transplantation: essentials and practical tips. Crit Care Nurs Q [Internet]. 2016 [cited 2021 Jul 3];39(3):227–40. Available from: https://pubmed.ncbi.nlm.nih.gov/27254639/ DOI: 10.1097/CNQ.0000000000000117
19. Takahashi J. iPS cell-based therapy for Parkinson's disease: a Kyoto trial. Regen Ther [Internet]. 2020 [cited 2021 Jul 3];13:18–22. Available from: https://www.sciencedirect.com/science/article/pii/S2352320420300614 DOI: 10.1016/j.reth.2020.06.002